System and methods are provided for harvesting one or more organs, e.g., a lung from a donor body. In one embodiment, a distal end of a tubular member is introduced into the donor body's vasculature via a percutaneous access site, and the tubular member is manipulated until the distal end of the tubular member is disposed within the thoracic duct. Fluid is removed from the thoracic duct through the tubular member to a location exterior to the patient's body, and one or more organs are removed from the donor body. Optionally, one or more parameters within the thoracic duct or other parameters of the donor body may be monitored and fluid removal may be adjusted to reduce fluid accumulation within the one or more organs.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.

Method for transferring one or more portions of fluid from a specimen tube, comprising: providing an elongate connector comprising an elongated tube having a lumen or through-hole extending between proximal and distal ends thereof, a Luer-compatible female taper provided on the proximal end of the connector, a flange provided proximate the distal end of the connector; providing a tube seal mounted on the distal end of the connector, the tube seal comprising an elastomeric member having a longitudinal axis, a proximal end, a distal end, and a through-hole extending therebetween, the distal end having a frustoconical or chamfered face forming a funnel, the elastomeric member having an outer diameter sized to sealingly engage with an inner surface of the specimen tube; advancing the distal end of the connector and the tube seal into the specimen tube, the funnel directing the first layer into the through-hole of the connector.

The invention is directed to the treatment of COVID-19 patients by withdrawing SARS-CoV-2 viral particles from the patient's circulation by apheresis using a binding agent in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. The reduction in viral particles may be combined by reduction of active gal-3 levels in the patient which may provide further relief of conditions associated with COVID-19 that may include symptoms associated with the cytokine storm that is associated with COVID-19 infection. Both SARS-CoV-2 viral particles and gal-3 may be bound by modified citrus pectin of less than sixty thousand Daltons. The process may be combined with the administration of supportive agents like antivirals, anti-inflammatories, immune based inhibitors, vitamins and modified citrus pectin.

The present disclosure relates to a patient monitor system with at least one collecting device which is programmed to collect behavior-related data and/or vital parameters of a patient. The patient monitor system further includes an output device and a calculation unit. The calculation unit is programmed to prompt or trigger the collecting device in order to collect the data and vital parameters. It is further programmed to generate instructions for controlling or regulating a medical treatment apparatus, and for outputting the instructions by the output device. The calculation unit is hereby further programmed to generate instructions and/or to have them output by the output device when the behavior-related data of the patient, or part of this data, and/or the vital parameters of the patient, or part these vital parameters do not lie in a value range respectively predetermined for them and/or lie beyond a limit value respectively predetermined for them.

The present invention pertains to present invention relates to a device comprising conjugate/s, and uses thereof in depleting at least one amine, specifically ammonia from body fluids. The present disclosure further provides systems, apparatus, conjugates, plurality of conjugates, and methods. More specifically, the conjugate comprising a particle bonded to at least one linker comprising a chain of n carbon atoms covalently bonded to m carbonyl groups, and at least one trapping agent A covalently bonded to the m.sup.th carbonyl group, (Formula I) wherein, n is an integer within the range of 5 to 15, and m is an integer within the range of 5 to 10, wherein trapping agent A is characterized by having the ability to capture or bind amine. In some optional embodiments, the amine is at least one of methylamine, dimethylamine or trimethylamine. In some embodiments, the linker of the conjugate of the disclosed device comprises a straight chain alkane and m carbonyl groups

The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.